BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial, ...
BridgeBio Pharma Inc.’s drug to treat a devastating muscle-wasting disorder met its goal in a late-stage trial, paving the ...
BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial. The ...
Autoimmune neuromuscular diseases may sound complex, but understanding them is the first step to getting the right care and ...
New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that ...
His parents Stephen and Jenny have asked Sheffield Children's NHS Foundation Trust to approve the use of drug givinostat, ...
If cancer is a disease of overabundance, where cells divide without restraint and tumors grow despite the body's best interests, then degenerative diseases are disorders of deprivation. When ...
A University of Missouri-led discovery could pave the way for improved diagnosis and treatment of unexplained movement ...
The University at Albany and Virginia Commonwealth University were awarded a $6.5 million NIH grant to establish a federal ...
The Chaparral Football Car Wash Fundraiser for SMA is happening Saturday, October 25, from 11 a.m. to 1 p.m. at Chaparral ...
Congenital muscular dystrophies (CMDs) comprise a heterogeneous group of inherited disorders primarily affecting muscle integrity and function, often with accompanying brain and ocular abnormalities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback